* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Neurocrine Biosciences's PEG Ratio or its related term are showing as below:
NBIX'
s PEG Ratio Range Over the Past 10 Years
Min: 0.53 Med: 1.08 Max: 1.57
Current: 0.53
During the past 13 years, Neurocrine Biosciences's highest PEG Ratio was 1.57. The lowest was 0.53. And the median was 1.08.
NBIX's PEG Ratio is ranked better than 87.43% of 366
companies
in the Drug Manufacturers industry
Industry Median: 1.695
vs NBIX: 0.53
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neurocrine Biosciences's PEG Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences's PEG Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Neurocrine Biosciences (NAS:NBIX) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Neurocrine Biosciences PEG Ratio Related Terms
Thank you for viewing the detailed overview of Neurocrine Biosciences's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBIX has been successfully added to your 